Immunomedics has developed an ADC called sacituzumab govitecan, which directly delivers chemotherapy SN-38 to TNBC tumours, which highly express Trop-2 and represents an unmet need within a highly treated cancer type. The company’s chief commercial officer Brendan Delaney explains the drug’s efficacious mechanism of action in this tumour type, as well as noting its success to date, particularly in tolerability and how Immunomedics is advancing the ADC in other Trop-2-expressing tumours.